Advertisements

Esomeprazole Krka

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Esomeprazole Krka

Property Description
Active ingredient Esomeprazole
Form Gastro-resistant tablets or hard capsules
Pharmacological class Proton Pump Inhibitor (PPI)
General purpose Sustained reduction of gastric acid secretion
Origin Synthetic, S-isomer of Omeprazole

What Type of Medicine is Esomeprazole Krka?

Esomeprazole Krka is a powerful synthetic prescription medicine classified as a Proton Pump Inhibitor (PPI), containing the single active ingredient, Esomeprazole. This medication is recognized in clinical guidelines as the most effective class of agents available for achieving profound acid suppression in the stomach, thus providing sustained relief from acid-related discomfort. The active compound, Esomeprazole, is chemically defined as the purified S-isomer of the older, racemic mixture, Omeprazole, belonging to the benzimidazole structure group, a property characterized by its consistent acid-suppressing profile.


Esomeprazole: The Chemical Origin and Unique Form

Esomeprazole Krka is supplied for oral administration as enteric-coated gastro-resistant tablets or hard capsules. This specialized formulation is crucial because the active substance, often in the form of Esomeprazole magnesium, is highly sensitive to acid. The gastro-resistant coating prevents its immediate breakdown in the stomach, ensuring reliable delivery to the intestine for proper absorption. This delivery system ensures that the full therapeutic potential of the drug is available to act on the proton pump enzyme (H^+/K^+-ATPase) in the stomach lining. By targeting and irreversibly deactivating this pump, Esomeprazole ensures a comprehensive reduction of gastric acid secretion, which is a mechanism clinically recognized for providing effective, sustained relief.

Advertisements

What side effects are possible with Esomeprazole Krka?

Possible side effects and safety information

The safety profile for esomeprazole is based on clinical data and regulatory surveillance, with adverse reactions formally classified by frequency and body system according to official standards.

Common reactions, occurring in up to 1 in 10 patients, primarily involve the Gastrointestinal system, including abdominal pain, constipation, diarrhea, flatulence, nausea, and vomiting. Effects on the Nervous system are also classified as common, most notably headache.

Uncommon side effects (occurring in up to 1 in 100 patients) may affect various systems, including insomnia (Psychiatric), dizziness (Nervous system), and rash or pruritus (Skin). Rare reactions (up to 1 in 1,000) include severe hypersensitivity reactions, such as anaphylactic shock.

Official labeling defines serious, very rare adverse reactions. These include Severe Cutaneous Adverse Reactions (SCARs) like Stevens-Johnson syndrome (SJS), as well as interstitial nephritis and hepatic failure.

Duration- and Population-Related Safety Patterns

Specific safety concerns are noted concerning the duration of exposure. Long-term use (generally over one year) is associated with an increased risk of bone fractures of the hip, wrist, or spine, particularly in older adults. Prolonged treatment (often over three months) has been linked to hypomagnesaemia (low magnesium levels).

Regulatory documents also state that use of this medicine may slightly increase the risk of certain gastrointestinal infections (e.g., Salmonella). Dosage constraints are in place for individuals with severe hepatic impairment, as noted in the official prescribing information.

Advertisements

Overdose and Emergency Response

Overdose Scope Official Regulatory Statements for Esomeprazole Krka
Documented Manifestations Overdose exposure, including single doses up to 280 mg, may result in transient and non-specific effects. Documented manifestations observed in high-dose situations can include signs related to the CNS and autonomic systems, such as confusion, blurred vision, fast heart rate (tachycardia), excessive sweating, and skin flushing. Other general symptoms officially reported are weakness, nausea, headache, and dry mouth.
Required Emergency Action If an overdose is suspected or has occurred, immediate medical attention is required. The official guidance explicitly directs individuals to "get medical help right away" or to "contact a Poison Control Center right away" for professional medical evaluation.
Management and Antidote The management of overdose is defined in regulatory documents as symptomatic and supportive treatment. No specific antidote is known for Esomeprazole, and due to extensive protein binding, the drug is not readily removed by standard hemodialysis procedures.

Overdose Profile Summary

The official overdose profile emphasizes that symptoms resulting from high-dose exposure are classified as generally transient, with no specific life-threatening complications listed as a direct result. Because the regulatory guidance confirms that no specific antidote is available, the entirety of the management protocol is focused on providing symptomatic and supportive care alongside continuous professional monitoring until the effects subside. This approach dictates the mandatory requirement to seek urgent medical attention for clinical assessment.

Advertisements

Therapeutic Uses of Esomeprazole Krka

Quick Facts: Primary Therapeutic Uses

  • Gastroesophageal Reflux Disease (GERD): May help in the resolution of symptoms related to acid reflux, such as heartburn.
  • Erosive Esophagitis: May support the healing of damage to the esophagus lining caused by acid.
  • Ulcer Risk Reduction: May contribute to the reduced occurrence of stomach ulcers associated with the continuous use of nonsteroidal anti-inflammatory drugs (NSAIDs).
  • Hypersecretory Conditions: May be used in the management of conditions causing the stomach to produce excess acid, such as Zollinger-Ellison syndrome.
  • H. pylori Eradication: Used as part of a combination regimen to eliminate Helicobacter pylori infection, which may reduce the risk of duodenal ulcer recurrence.

Esomeprazole Krka is an established medication used in the therapeutic management of various gastrointestinal conditions related to excessive stomach acid production. The drug is primarily indicated for the short-term treatment and subsequent maintenance of healing of erosive esophagitis, which involves acid-related injury to the food pipe.

It is also used to manage the symptoms associated with Gastroesophageal Reflux Disease (GERD), including recurring heartburn. The medication may also be prescribed to contribute to the reduced risk of gastric ulcers in individuals who are receiving extended therapy with nonsteroidal anti-inflammatory drugs (NSAIDs). Furthermore, Esomeprazole Krka is applied in specific combination treatments for the eradication of the H. pylori bacteria to support healing and reduce ulcer recurrence. Its utility extends to the long-term control of pathological hypersecretory conditions. Always follow the guidance of a healthcare professional regarding usage and duration of treatment.

Regulatory References

  1. EMA therapeutic overview
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Esomeprazole Krka

Official regulatory documents strictly define patient eligibility for Esomeprazole Krka, focusing on absolute exclusions, age, and organ function.

Absolute Contraindications

Esomeprazole Krka must not be used by individuals with known hypersensitivity to esomeprazole, any product excipients, or to the class of substituted benzimidazoles. Use is also strictly contraindicated in patients receiving the antiretroviral medications nelfinavir or rilpivirine.

Age-Related Eligibility

The medicine is approved for use in adults and adolescents (ge 12 years) for most indications. Pediatric use is approved for children (1 to 11 years) and infants as young as one month for specific acid-related conditions; however, safety and effectiveness are not established in infants younger than one month.

Condition-Based Restrictions

Eligibility is conditional for certain health statuses. Patients with severe liver impairment (Child-Pugh Class C) are limited to a maximum daily intake of 20 mg. While no dose adjustment is required for severe renal insufficiency, treatment should be administered with caution. Furthermore, gastric malignancy must be excluded prior to starting therapy.

Pregnancy and Lactation

Use is generally not recommended during pregnancy or lactation unless deemed essential, as stated in official labeling.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Esomeprazole is governed by two principal mechanisms: its effect on gastric pH and its modulation of Cytochrome P450 (CYP) enzymes, particularly CYP2C19.

Co-administration with Rilpivirine-containing products and Nelfinavir is formally contraindicated in regulatory documents. Use with Clopidogrel is generally avoided as Esomeprazole decreases the exposure of its active metabolite via CYP2C19 inhibition.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Substances/Outcomes
Gastric pH-Dependent Absorption of Ketoconazole, Erlotinib, and Iron Salts is decreased; Digoxin exposure may be increased.
CYP Enzyme Inhibition May increase plasma levels of drugs like Cilostazol, Tacrolimus, and Warfarin, requiring monitoring of INR.
CYP Enzyme Induction Use of St. John's Wort or Rifampin should be avoided as they can reduce Esomeprazole plasma levels.

Co-administration with Methotrexate requires consideration of temporary withdrawal during high-dose therapy due to a risk of prolonged serum concentrations. Furthermore, Esomeprazole treatment must be stopped for at least five days before specific diagnostic tests, such as Chromogranin A (CgA) measurement, to prevent test interference.

Advertisements

Mechanism of Action

How Esomeprazole Krka Works: Mechanism of Action

Esomeprazole operates by selectively targeting the H^+/ K^+-ATPase enzyme, commonly known as the proton pump, found on the secretory surface of the gastric parietal cells. The compound is administered as an inactive prodrug, which is absorbed systemically and then selectively accumulates in the highly acidic secretory canaliculi of these cells. In this low pH environment, the drug undergoes an essential acid-catalyzed chemical transformation, converting it into its active sulfonamide metabolite. This activation focuses the drug's transformation directly at the site of acid production.

The active metabolite then forms a covalent, irreversible bond with specific cysteine residues on the H^+/ K^+-ATPase enzyme. This firm chemical interaction blocks the final step in the acid secretion cascade, leading to a profound and sustained suppression of gastric acid output. Since the inhibition is irreversible, the pump's function can only be restored by the gastric parietal cell synthesizing new H^+/ K^+-ATPase proteins. This mechanism results in prolonged acid modulation, maintaining the physiological effect beyond the drug's systemic elimination half-life.

Advertisements

Dosage and Administration Information

How to Use Esomeprazole Krka: Official Administration Guidelines

This section outlines the instructions for the administration of Esomeprazole Krka.


Administration and Timing

Guideline Official Instruction
Route of Administration Oral.
Timing in Relation to Meals Take the medicine at least one hour before a meal (for delayed-release capsules and tablets).
Frequency Typically once daily, though some regimens (e.g., H. pylori eradication) require twice daily dosing.
Dosing Schedule Dosage is individualized by the physician, with defined rules for adults and pediatric patients down to 1 month of age.
Treatment Course The medicine must be taken for the full duration prescribed by the doctor, even if symptoms improve.

Procedural Requirements

Swallowing: The delayed-release capsule or tablet must be swallowed whole with a drink of water. It is a critical instruction that the medicine must not be chewed or crushed due to its gastro-resistant coating, which protects the active substance from stomach acid.

Alternative Administration: For patients unable to swallow the capsule whole, the capsule can be opened, and the contained pellets mixed with a small amount (e.g., one tablespoon) of cool, soft applesauce or dispersed in a half-glass of non-carbonated water. The resulting mixture must be swallowed immediately, or within 30 minutes of preparation, without chewing the pellets.

Missed Dose: If a dose is missed, take it as soon as it is remembered. However, if it is almost time for the next scheduled dose (e.g., less than 12 hours away for once-daily use), the missed dose should be skipped, and the regular schedule resumed. A double dose must not be taken to make up for a missed one.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Esomeprazole Krka


Evidence for Healing and Symptom Relief: Erosive Esophagitis and GERD

Research exploring the use of this medicine in conditions marked by outcomes linked to inflammatory or irritative states includes short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies examined adult populations with endoscopically confirmed erosive esophagitis (EE) and those experiencing symptoms of Gastroesophageal Reflux Disease (GERD). Research examined outcomes related to endoscopic healing of the esophagus lining; studies also monitored patient-reported outcomes describing perceived discomfort, such as the number of heartburn-free days.

What remains uncertain is the sufficiency of the existing data for certain groups, as the evidence base for children, especially those aged 1 to 5 years, is often based on modest sample sizes. Comparative evidence exists against older compounds; however, the meaning of small statistical differences reported is not consistently well-characterized.


Evidence for Relapse Prevention and Maintenance

Research exploring the continued use of the medicine was evaluated in studies observing the reoccurrence of acid-related damage in individuals who have achieved initial healing. These studies include intermediate-term, controlled withdrawal studies with follow-up durations typically set at six months.

Research examined outcomes related to endoscopic relapse and outcomes related to physical discomfort over time. Studies monitored the proportion of patients who maintained healing and reported continuous freedom from symptoms over the observation period.


Evidence for H. pylori Eradication and Other Specialized Uses

The research examined the use of this medication as a component of specific multi-drug regimens to address Helicobacter pylori infection, which is a key factor in certain types of ulcers. These studies are typically short-term comparative RCTs. Research examined measures related to the bacterial eradication rate, confirmed by laboratory testing following the multi-drug course. Research also explored outcomes related to certain rare conditions, such as Zollinger-Ellison Syndrome, which are marked by severe acid production.


What Remains Uncertain in the Research

Research contributes to the broader evidence landscape but also highlights key areas where certainty remains low. Long-term effects are not fully established across all patient demographics, particularly for outcomes that require observation periods beyond one year. Data show patterns related to insufficient information for infants under one year of age, and specific data for outcomes related to severe liver impairment are also often limited. Comparative evidence is limited between this medication and some of the newest compounds in the PPI class; much of the existing trial data examines it against older compounds.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Esomeprazole Krka (FAQ)


Q: What conditions is Esomeprazole Krka officially approved to treat?

Official regulatory documents indicate that Esomeprazole Krka is approved for several conditions related to excess stomach acid. These include the treatment of erosive reflux esophagitis, the long-term management of healed esophagitis, and the symptomatic treatment of Gastroesophageal Reflux Disease (GERD). It is also used in multi-drug regimens for H. pylori eradication and to manage conditions like Zollinger-Ellison Syndrome.

Q: Can Esomeprazole Krka be used for long-term treatment?

Yes, Esomeprazole Krka is indicated for certain long-term uses, such as the maintenance of healing in esophagitis and in specific cases of high acid production. However, official product information indicates that prolonged use, generally exceeding one year, has been associated with specific safety patterns, including an increased risk of bone fractures and low magnesium levels.

Q: What is the difference between Esomeprazole Krka and omeprazole?

Esomeprazole Krka contains esomeprazole, which is chemically defined as the S-isomer of the older drug, omeprazole. This means esomeprazole is a purified version of the active compound. Regulatory literature suggests this chemical distinction allows for higher and more predictable drug levels in the body after repeated dosing compared to the older omeprazole mixture.

Q: Can Esomeprazole Krka affect my liver or kidney function?

The medicine is primarily processed by the liver, and because of this, regulatory dosage constraints are advised for individuals who have severe hepatic impairment. While no dosage adjustment is generally required for kidney impairment, official labeling advises caution. Rarely, severe reactions involving the liver or kidneys have been noted in safety monitoring.

Q: Are there any ingredients in Esomeprazole Krka that cause common allergies?

Official labeling requires the declaration of excipients (inactive ingredients) that may cause issues. Esomeprazole Krka contains excipients, including lactose and sucrose. The use of the medicine is formally contraindicated in individuals with a known hypersensitivity to the active drug, any excipient, or other benzimidazole compounds.

Q: Why is it said that Esomeprazole Krka should be taken before a meal?

Regulatory instructions define the timing of administration as being at least one hour before a meal. Official pharmacokinetic data indicates this timing is crucial because the drug is most effective when it is absorbed from the small intestine before food intake fully activates the proton pumps in the stomach lining. Taking it before a meal helps optimize its acid-suppressing ability.

Q: Are there studies that examine the use of Esomeprazole Krka in older adults?

Yes, official regulatory reviews include specific studies examining the drug's properties in the elderly patient population. These pharmacokinetic studies indicated that no general dosage adjustment is required for older adults. However, safety information does note that long-term risks, like bone fractures, are of particular concern in this demographic.

Q: How does Esomeprazole Krka differ from stomach acid neutralizers (antacids)?

Esomeprazole Krka, as a Proton Pump Inhibitor (PPI), works by entering the stomach lining cells and irreversibly blocking the mechanism that creates acid, leading to a profound, sustained reduction in acid secretion. In contrast, antacids work only by neutralizing the acid that is already present in the stomach for quick, short-term relief.

Q: Can taking Esomeprazole Krka make me more sensitive to the sun?

While not a common side effect, official post-marketing safety reports include instances of increased sensitivity to sunlight (photosensitivity). The incidence rate for this specific side effect is noted as not known, but patients should be aware of this possibility.

Q: How quickly does Esomeprazole Krka usually start to work?

Studies and official patient information indicate that many people start to feel an improvement in their symptoms within 2 to 3 days of starting the medicine. However, the full, maximum acid-suppressing effect of the drug typically requires consistent use over a longer period, sometimes up to 4 weeks.

Q: Is there a generic version of Esomeprazole Krka?

Yes, the active ingredient, esomeprazole magnesium, is widely available as a generic drug in various regulated dosage forms. Official drug registers, such as those maintained by the FDA and EMA, list multiple generic manufacturers for this active ingredient.

Q: What is the connection between Esomeprazole Krka and Vitamin B12 levels?

Official regulatory warnings state that prolonged daily treatment with this class of medicine, typically lasting longer than one year, may be associated with a reduced absorption of Vitamin B12. This can, in rare instances, lead to a Vitamin B12 deficiency.

Q: Can I take Esomeprazole Krka if I have lactose intolerance?

The tablets and capsules contain lactose as an excipient. Official patient information advises that individuals with rare hereditary problems of galactose intolerance or lactose deficiency should not take this medicine.

Q: Does Esomeprazole Krka interact with alcohol?

While there is no formal severe contraindication listed, the use of alcohol may, in some individuals, aggravate symptoms of the underlying acid-related condition being treated. For specific interaction information, the official patient information leaflet should always be consulted.

Q: What is the half-life of Esomeprazole Krka?

Pharmacokinetic studies in official labeling indicate that the terminal plasma elimination half-life of the drug is approximately 1 to 1.5 hours. However, due to its irreversible chemical mechanism, the profound acid-suppressing effect on the stomach lasts much longer than the drug's short half-life.

Q: Does Esomeprazole Krka have a warning about driving or operating machinery?

Official product information notes that some patients may experience uncommon side effects that affect the nervous system, such as dizziness or visual disturbances. Patients who experience these effects are cautioned to be aware of the impact on their ability to drive or operate machinery.

Q: Is Esomeprazole Krka available over the counter in some countries?

While the brand name Esomeprazole Krka is generally available only by prescription, the active ingredient, esomeprazole, is available in some countries in specific lower-strength formulations for non-prescription (over-the-counter) use.

Q: Can Esomeprazole Krka be taken with cough and cold medicines?

Official regulatory interaction tables do not list specific severe contraindications for common cough and cold medicines. Patients should always consult the official patient leaflet, as the potential for interactions exists.

Q: Is it important to take Esomeprazole Krka at the same time every day?

Yes, regulatory patient instructions emphasize that for the medicine to maintain consistent drug levels and maximize the acid-blocking effect, it is generally recommended to take it at the same time every day.

Q: Does Esomeprazole Krka interact with birth control pills?

Regulatory studies have examined the use of esomeprazole alongside oral contraceptives (such as those containing ethinyl estradiol and levonorgestrel). These studies have not shown any clinically relevant interaction that would require a dose change for the birth control pill.

Q: Are there any reported cases of long-term memory issues with Esomeprazole Krka?

Official post-marketing data collected by regulatory bodies include reports of effects on the central nervous system, such as confusion. However, 'long-term memory issues' are not listed as a primary or common adverse effect, and the reported incidence is noted as not known.

Q: Does Esomeprazole Krka cause a metallic taste in the mouth?

Official adverse reaction lists note that taste disturbance (dysgeusia) is an uncommon side effect. This type of disturbance can sometimes be perceived by patients as a metallic taste in the mouth.

Q: Is Esomeprazole Krka the same drug as Nexium?

Yes, Esomeprazole is the active pharmaceutical ingredient found in both Esomeprazole Krka and the well-known original brand-name medicine, Nexium. They contain the same compound and share the same therapeutic effect.

Q: Can Esomeprazole Krka be taken with painkillers like ibuprofen?

Regulatory information indicates that Esomeprazole is often used as a protective measure to prevent gastric ulcers that can be caused by long-term use of NSAID painkillers like ibuprofen. Patients should consult the official patient leaflet for specific guidance on combining this medicine with painkillers.

Advertisements

How should Esomeprazole Krka be stored and disposed of?

Storage and Disposal of Esomeprazole Krka Hard Capsules

Official Storage Requirements

Esomeprazole Krka must be stored under specific conditions to maintain its stability. The product must not be stored above 25 C and must be kept in its original package to protect from moisture. In the US, the typical mandated storage range is 20 C to 25 C (68 F to 77 F).

If the capsules are supplied in a bottle, the container must be kept tightly closed, and the contents must be used within 3 months after first opening to comply with labeled stability conditions. All medication must be kept out of the sight and reach of children.

Disposal Protocol

To discard unused or expired Esomeprazole Krka, patients must not throw away medicines via wastewater or household waste. Disposal must be carried out in accordance with local pharmaceutical waste requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Esomeprazole Krka found in:

A-Z Index: